Wall Street Zen upgraded shares of Perrigo (NYSE:PRGO - Free Report) from a hold rating to a buy rating in a report published on Saturday.
Perrigo Stock Down 0.2%
Shares of NYSE PRGO traded down $0.06 during mid-day trading on Friday, reaching $27.05. 39,983 shares of the company's stock were exchanged, compared to its average volume of 1,573,754. The firm has a market capitalization of $3.72 billion, a price-to-earnings ratio of -23.12 and a beta of 0.45. The company has a current ratio of 2.56, a quick ratio of 1.77 and a debt-to-equity ratio of 0.94. The business has a fifty day simple moving average of $26.12 and a 200 day simple moving average of $26.19. Perrigo has a twelve month low of $23.14 and a twelve month high of $30.93.
Perrigo (NYSE:PRGO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.56 by $0.04. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the business earned $0.29 earnings per share. Perrigo's quarterly revenue was down 3.5% on a year-over-year basis. As a group, equities analysts expect that Perrigo will post 2.56 EPS for the current fiscal year.
Perrigo Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 17th. Stockholders of record on Friday, May 30th will be paid a $0.29 dividend. The ex-dividend date of this dividend is Friday, May 30th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 4.29%. Perrigo's dividend payout ratio (DPR) is -88.55%.
Insider Buying and Selling
In other Perrigo news, EVP Ronald Craig Janish sold 7,800 shares of Perrigo stock in a transaction on Monday, March 10th. The shares were sold at an average price of $27.44, for a total value of $214,032.00. Following the completion of the transaction, the executive vice president now directly owns 33,666 shares of the company's stock, valued at $923,795.04. This trade represents a 18.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.70% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Perrigo
Large investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD raised its position in Perrigo by 41.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 11,073,026 shares of the company's stock worth $310,488,000 after acquiring an additional 3,227,487 shares during the period. Dimensional Fund Advisors LP increased its stake in Perrigo by 2.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 7,135,741 shares of the company's stock worth $200,085,000 after buying an additional 146,211 shares in the last quarter. Deprince Race & Zollo Inc. increased its stake in Perrigo by 1.1% during the 4th quarter. Deprince Race & Zollo Inc. now owns 4,557,844 shares of the company's stock worth $117,182,000 after buying an additional 50,728 shares in the last quarter. Cooke & Bieler LP increased its stake in Perrigo by 4.1% during the 4th quarter. Cooke & Bieler LP now owns 3,573,651 shares of the company's stock worth $91,879,000 after buying an additional 139,650 shares in the last quarter. Finally, Sound Shore Management Inc. CT grew its position in shares of Perrigo by 23.1% in the first quarter. Sound Shore Management Inc. CT now owns 3,285,167 shares of the company's stock valued at $92,116,000 after purchasing an additional 616,387 shares in the last quarter. Hedge funds and other institutional investors own 95.91% of the company's stock.
Perrigo Company Profile
(
Get Free Report)
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Featured Stories
Before you consider Perrigo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perrigo wasn't on the list.
While Perrigo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.